{"title":"生物类似药在类风湿关节炎中的作用——从研发到销售的过程和世界趋势","authors":"H. Matsuno","doi":"10.15761/ccrr.1000509","DOIUrl":null,"url":null,"abstract":"Figures 1 and 2 shows the trend of the sale of advanced therapeutic drugs for rheumatoid arthritis (RA) currently available commercially in Japan. After the release of infliximab in 2003, biological products were introduced to the market with great frequency, and biological products with different mechanisms of action and dosing regimens became available (the use of rituximab for RA is not approved in Japan, unlike in overseas countries). Ten years after the release of the first biological product in Japan, the sale of Janus kinase inhibitors was promoted, and biosimilars (BSs) were also actively marketed.","PeriodicalId":72607,"journal":{"name":"Clinical case reports and reviews","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2021-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Role of biosimilars in rheumatoid arthritis - Process from R & D to marketing and trends in the world\",\"authors\":\"H. Matsuno\",\"doi\":\"10.15761/ccrr.1000509\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Figures 1 and 2 shows the trend of the sale of advanced therapeutic drugs for rheumatoid arthritis (RA) currently available commercially in Japan. After the release of infliximab in 2003, biological products were introduced to the market with great frequency, and biological products with different mechanisms of action and dosing regimens became available (the use of rituximab for RA is not approved in Japan, unlike in overseas countries). Ten years after the release of the first biological product in Japan, the sale of Janus kinase inhibitors was promoted, and biosimilars (BSs) were also actively marketed.\",\"PeriodicalId\":72607,\"journal\":{\"name\":\"Clinical case reports and reviews\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical case reports and reviews\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.15761/ccrr.1000509\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical case reports and reviews","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/ccrr.1000509","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Role of biosimilars in rheumatoid arthritis - Process from R & D to marketing and trends in the world
Figures 1 and 2 shows the trend of the sale of advanced therapeutic drugs for rheumatoid arthritis (RA) currently available commercially in Japan. After the release of infliximab in 2003, biological products were introduced to the market with great frequency, and biological products with different mechanisms of action and dosing regimens became available (the use of rituximab for RA is not approved in Japan, unlike in overseas countries). Ten years after the release of the first biological product in Japan, the sale of Janus kinase inhibitors was promoted, and biosimilars (BSs) were also actively marketed.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
